Trial · NCT03500549
Results by group137
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 137
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP | Pegcetacoplan to Pegcetacoplan | 2.37 | Standard Error 0.363 | Grams per deciliter (g/dL) | |
| Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP | Eculizumab to Pegcetacoplan | -1.47 | Standard Error 0.666 | Grams per deciliter (g/dL) | |
| Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP | Pegcetacoplan to Pegcetacoplan | 85.4 | Percentage of subjects | ||
| Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP | Eculizumab to Pegcetacoplan | 15.4 | Percentage of subjects | ||
| LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP | Pegcetacoplan to Pegcetacoplan | -135.82 | Standard Error 6.543 | 10^9 cells/ liter (L) | |
| LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP | Eculizumab to Pegcetacoplan | 27.79 | Standard Error 11.859 | 10^9 cells/ liter (L) | |
| LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP | Pegcetacoplan to Pegcetacoplan | -14.76 | Standard Error 42.708 | Units (U)/L | |
| LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP | Eculizumab to Pegcetacoplan | -10.12 | Standard Error 71.025 | Units (U)/L | |
| LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP | Pegcetacoplan to Pegcetacoplan | 9.22 | Standard Error 1.607 | Score on a scale | |
| LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP | Eculizumab to Pegcetacoplan | -2.65 | Standard Error 2.821 | Score on a scale | |
| Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16 | Pegcetacoplan to Pegcetacoplan | 75.6 | Percentage of subjects | ||
| Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16 | Eculizumab to Pegcetacoplan | 0.0 | Percentage of subjects | ||
| Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16 | Pegcetacoplan to Pegcetacoplan | 78.0 | Percentage of subjects | ||
| Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16 | Eculizumab to Pegcetacoplan | 2.6 | Percentage of subjects | ||
| Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16 | Pegcetacoplan to Pegcetacoplan | 34.1 | Percentage of subjects | ||
| Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16 | Eculizumab to Pegcetacoplan | 0.0 | Percentage of subjects | ||
| LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP | Pegcetacoplan to Pegcetacoplan | -17.78 | Standard Error 2.727 | Micromole (μmol)/L | |
| LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP | Eculizumab to Pegcetacoplan | 4.15 | Standard Error 4.477 | Micromole (μmol)/L | |
| LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP | Pegcetacoplan to Pegcetacoplan | -0.02 | Standard Error 0.033 | g/L | |
| LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP | Eculizumab to Pegcetacoplan | 0.12 | Standard Error 0.063 | g/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03500549/results